Patent · US Active

Potent and selective inhibitors of hepatitis C virus

US9932326B2 · kind B2 · utility

1Cited by

1References

10Claims

0Family size

Assignees

COCRYSTAL PHARMA, INC. · US
EMORY UNIVERSITY · US

Inventors

Steven J. Coats · McDonough, US
Franck Amblard · Tucker, US
Hongwang Zhang · Tucker, US
Longhu Zhou · Atlanta, US
Richard Anthony Whitaker · Amarillo, US
Tamara Rosario McBrayer · Tucker, US
Raymond F. Schinazi · Decatur, US
Junxing Shi · Duluth, US

Key dates

Filing date	Nov 10, 2015
Grant date	Apr 3, 2018
Priority date	—
Expiry date	Nov 10, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D413/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.